Theravance Biopharma (TBPH) Q2 2026 earnings — TrendMatrix coverage
BEAT+161.7% vs estimateEPS $0.18 vs $0.07 estVerdict Buy (Wait) → Hold
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Event detail · Q2 2026
Key numbers
- Adjusted EPS
- $0.18
- Estimate
- $0.07
- Surprise
- +161.7%
- Score at report (before → after)
- 5.8 → 5.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Report record · Q2 2026
How the report landed
Theravance Biopharma (TBPH) beat the $0.07 estimate with adjusted EPS of $0.18 — a large 161.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.8/10) to Hold at 5.8/10 after the report.